TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06275386

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Paclitaxel Drug-coated balloon
Description: Percutaneous coronary intervention of the actual CTO body with a paclitaxel drug-coated balloon.
Study: NCT06135974

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LC106
Description: Tablet containing at least 2 x 10\^6 CFU/tablet, and comprised of 6 strains of Lactobacillus crispatus

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LC106
Description: Tablet containing at least 2 x 10\^6 CFU/tablet, and comprised of 6 strains of Lactobacillus crispatus

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LC106
Description: Tablet containing at least 2 x 10\^6 CFU/tablet, and comprised of 6 strains of Lactobacillus crispatus

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LC115
Description: Tablet containing at least 2 x 10\^6 CFU/tablet, and comprised of 15 strains of Lactobacillus crispatus

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Vaginal tablets containing primarily microcrystalline cellulose and no live bacteria

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metronidazole Oral
Description: Metronidazole tablet orally twice daily for 7 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metronidazole Oral
Description: Metronidazole tablet orally twice daily for 7 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metronidazole Oral
Description: Metronidazole tablet orally twice daily for 7 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metronidazole Oral
Description: Metronidazole tablet orally twice daily for 7 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Metronidazole Oral
Description: Metronidazole tablet orally twice daily for 7 days
Study: NCT04879966

Intervention type: DRUG
Intervention: Infliximab
Description: Infliximab was used as induction therapy in UC patients, the maintenance treatment was decided by the researcher

Intervention type: DRUG
Intervention: Corticosteroid
Description: Corticosteroids was used as induction therapy in UC patients, the maintenance treatment was decided by the researcher
Study: NCT06166966

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Flipped Education Model
Description: The effect of the Inside Out Education Model on the course success of nursing students.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Flipped Education Model
Description: The effect of the Inside Out Education Model on the course success of nursing students.
Study: NCT06023706

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capsaicin 179 Mg Cutaneous Patch
Description: 1 patch applied once for 1 hour

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Capsaicin low concentration patch (capsaicin 0,04%, 3,2 mg/cm2)
Description: 1 patch applied once for 1 hour
Study: NCT04987502

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virtual Reality
Description: 8 sessions of virtual reality with 3D audio and visual rendering

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard treatment
Description: counselling, relaxation techniques, sound enrichment
Study: NCT05097443

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Orelabrutinib+R-CHOP; Orelabrutinib+R-DA-EPOCH; Orelabrutinib+R-HD MTX;Orelabrutinib+R+other chemotherapies
Description: Orelabrutinib+R-CHOP： Orelabrutinib 150mg qd; R-CHOP：Rituximab 375mg/m2 d0, Cyclophosphamide 750mg /m2 d1, Doxorubicin 50mg /m2 or Doxorubicin liposome 30-40 mg /m2 d1, Vincristine 1.4mg /m2 or Vindesine 3mg /m2 d1, Prednisone 100mg d1-5.~Orelabrutinib+R-DA-EPOCH： Orelabrutinib 150mg qd； R-DA-EPOCH：Rituximab 375mg/m2 d0, Etoposide 50mg/ m2, Epirubicin 15mg/ m2, Vincristine 0.4mg/ m2, d1-4, Cyclophosphamide 750mg/ m2 d5, Prednisone 60mg/ m2 d1-5.~Orelabrutinib+R-HD-MTX: Orelabrutinib 150mg qd; R-HD-MTX: Rituximab 375mg/m2 d0, Methotrexate 3.5g/ｍ2 d1.~Orelabrutinib+ R+other regimens: Orelabrutinib 150mg qd； R+other regimens: Rituximab 375mg/m2 d0. The dose of other drugs depends on the regimen.~All regimens follow every 21 days is one cycle, which can be extended to 28 days per cycle according to patients' specific tolerance.~Dose adjustments of Orelabrutinib are allowed. The initial dose is 150 mg, QD, while the first adjustment is 100 mg, QD and the second adjustment is 50 mg, QD.
Study: NCT05258149

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: JJVC Investigational Multifocal Contact Lenses
Description: TEST

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: JJVC Investigational Multifocal Contact Lenses
Description: TEST

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dailies Total 1® Multifocal Contact Lenses
Description: CONTROL

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dailies Total 1® Multifocal Contact Lenses
Description: CONTROL
Study: NCT06334848

Intervention type: PROCEDURE
Group type: OTHER
Intervention: transobturator tape
Description: Women with stress urinary incontinence are treated by transobturator tape versus mini sling

Intervention type: PROCEDURE
Group type: OTHER
Intervention: transobturator tape
Description: Women with stress urinary incontinence are treated by transobturator tape versus mini sling
Study: NCT05044871

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pamiparib
Description: 40mg PO. bid.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: 7.5mg/kg IV. D1 (q3w.)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: 7.5mg/kg IV. D1 (q3w.)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: 7.5mg/kg IV. D1 (q3w.)
Study: NCT06242262

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Deep neuromuscular block
Description: Patients will receive deep neuromuscular block by using cis-atracurium. After tracheal intubation for 15 min, a cis-atracurium pump will be started, and its rate will be adjusted to maintain a post-tetanic count (PTC) in the 1-2 range.

Intervention type: OTHER
Group type: OTHER
Intervention: Moderate neuromuscular block
Description: Patients will receive moderate neuromuscular block by using cis-atracurium. Pump delivery of cis-atracurium will be started when the TOF count returned to 2. The TOF count is maintained between 1 and 3 by adjusting the pump rate
Study: NCT05130099

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Interdisciplinary complex intervention
Description: The interdisciplinary complex intervention lasts 12 weeks and includes the 4 following components;~Patient-education: a 2-hours group-based digital session, including information about fatigue, training theory, psychological strategies and nutrition, all in relation to chronic fatigue (CF).~Physical exercise program: two weekly sessions with aerobic exercise and resistance training. The participants are instructed to do the same program in the unsupervised sessions as in the supervised sessions. After the first 12 weeks exercise period, the participant and the physiotherapist makes an individually tailored plan for exercise and follow-up the next 12 weeks.~Cognitive behavioral program: 6 group-based online sessions lead by two psychologists, based on elements from cognitive behavioral therapy to reduce and/or manage CF. Each session lasts for 135 minutes.~Nutritional counselling: 3 individual sessions by a clinical dietitian. Each session lasts for 30-60 minutes.
Study: NCT06480227

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Solyx Single-incision Sling
Description: Minimally invasive mesh device placed to treat stress urinary incontinence.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Bulkamid Transurethral Bulking Agent
Description: Minimally invasive bulking agent injections used to bulk up the tissue surrounding the urethra to treat stress urinary incontinence. Up to 2 treatments within 12 months are allowed
Study: NCT05390294

Intervention type: PROCEDURE
Intervention: Surgical intervention with or without postoperative adjuvant therapy
Description: Surgical intervention with or without postoperative adjuvant therapy

Intervention type: PROCEDURE
Intervention: Surgical intervention with or without postoperative adjuvant therapy
Description: Surgical intervention with or without postoperative adjuvant therapy
Study: NCT06322589

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: SOD like Super Drink
Description: consume 1 bottle per day

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo drink
Description: consume 1 bottle per day
Study: NCT04780360

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cayanoacrylate tissue adhesives
Description: Cyanoacrylates are a family of strong fast-acting adhesives with industrial, medical, and household uses. They are various esters of cyanoacrylic acid. The acryl groups in the resin rapidly polymerize in the presence of water to form long, strong chains

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Silk suture
Description: Non Absorbalble suture materiel used to fixed the edges of the incision in place until healing
Study: NCT06341582

Intervention type: DIAGNOSTIC_TEST
Intervention: End-tidal carbon monoxide-corrected (ETCOc)
Description: Early postnatal ETCOc levels

Intervention type: DIAGNOSTIC_TEST
Intervention: End-tidal carbon monoxide-corrected (ETCOc)
Description: Early postnatal ETCOc levels
Study: NCT05920382

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Radiofrequency ablation of peripheral nerves.
Description: Randomized double-blind clinical trial where we will apply thermal radiofrequency to the sensory terminal branches of the femoral nerve in the knee, including the vasto medial nerve, vasto lateral nerve, vasto intermedio nerves, and the infrapatellar branch of the saphenous nerve.
Study: NCT05553730

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Digital Buddy program
Description: Six months of ICT and psychoeducation delivered by youth mentors via an e-learning platform
Study: NCT05920382

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radiofrequency ablation of peripheral nerves.
Description: Randomized double-blind clinical trial where we will apply thermal radiofrequency to the sensory terminal branches of the femoral nerve in the knee, including the vasto medial nerve, vasto lateral nerve, vasto intermedio nerves, and the infrapatellar branch of the saphenous nerve.
Study: NCT05694923

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Empagliflozin 10 MG
Description: non fatty liver non alcoholic patients Will receive empaglifizon sodium glucose cotransporter in minimum dose 10 mg
Study: NCT05044871

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab
Description: 200mg IV. D1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab
Description: 200mg IV. D1
Study: NCT06116799

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Orthotic
Description: Arch support orthotic

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Orthotic
Description: Arch support orthotic

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Orthotic
Description: Arch support orthotic
Study: NCT06149000

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Avulux Lenses
Description: Avulux lenses are specialized eyewear designed to reduce specific wavelengths of light to alleviate symptoms in individuals who experience light sensitivity and migraines

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Avulux Lenses
Description: Avulux lenses are specialized eyewear designed to reduce specific wavelengths of light to alleviate symptoms in individuals who experience light sensitivity and migraines

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Placebo Lenses
Description: Lenses that will look identical to Avulux lenses without the medical benefits

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Lenses
Description: Lenses that will look identical to Avulux lenses without the medical benefits
Study: NCT05044871

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab paclitaxel
Description: 125mg / m2 IV. D1, 8 (q3w).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab paclitaxel
Description: 125mg / m2 IV. D1, 8 (q3w).
Study: NCT06324968

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Positive serology for anti-SSA
Description: Blood sample which detect serology for anti-SSA.
Study: NCT05809856

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: GrOwnValve - novel heart valve replacement approach
Description: The autologous GrOwnValve is implanted into a stent before it is implanted via minimal-invasive transcatheter technique into the patients with high-grade pulmonary valve insufficiency and right ventricular dilatation. Control intervention/Reference test: Since the study is designed for investigating the safety of the procedure, there will not be a control group. However, the outcomes will be compared as a non-inferiority analysis with the standard of current medical care (Edwards SAPIEN 3 or Medtronic's Melody, both bioprosthetic transcatheter pulmonary valves).
Study: NCT05986851

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azeliragon
Description: Oral capsule
Study: NCT06493630

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Hypnobreastfeeding Education
Description: Hypnobreastfeeding Education: Monitoring breastfeeding myths, breastfeeding expectations and breastfeeding self-efficacy with hypnobreastfeeding education
Study: NCT05044871

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab + Nab paclitaxel (intense dose-dense)
Description: Bevacizumab 7.5mg/kg IV. D1, 15 (Q4w). + Nab paclitaxel 100mg / m2 IV. D1, 8, 15 (Q4w).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab + Nab paclitaxel (intense dose-dense)
Description: Bevacizumab 7.5mg/kg IV. D1, 15 (Q4w). + Nab paclitaxel 100mg / m2 IV. D1, 8, 15 (Q4w).
Study: NCT05432752

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Concussion Pen
Description: Device will measure the distance from the eye to the Concussion Pen for ocular motor functions.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Concussion Pen
Description: Device will measure the distance from the eye to the Concussion Pen for ocular motor functions.
Study: NCT06533579

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Dose Level 1, VNX-101
Description: Adeno-associated viral vector encoding the CD3/CD19 Bi-Specific T-Cell Engager (AAV.CD3/CD19), Single IV infusion

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Dose Level 2, VNX-101
Description: Adeno-associated viral vector encoding the CD3/CD19 Bi-Specific T-Cell Engager (AAV.CD3/CD19), Single IV infusion

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Dose Level 3, VNX-101
Description: Adeno-associated viral vector encoding the CD3/CD19 Bi-Specific T-Cell Engager (AAV.CD3/CD19), Single IV infusion

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Dose Level 4, VNX-101
Description: Adeno-associated viral vector encoding the CD3/CD19 Bi-Specific T-Cell Engager (AAV.CD3/CD19), Single IV infusion
Study: NCT06304363

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Braining
Description: Braining is a clinical invention that helps patients in psychiatry to start and execute physical exercise (PE) regularly in psychiatric care. The core components are basic moderate to vigorous aerobic group training session and motivational work led by the psychiatric staff. Braining is used as add-on treatment to regular psychiatric care and is included in the patient care plan.
Study: NCT05092945

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cold exposure
Description: The liquid-conditioned tube suit will be perfused with 18°C water using a temperature- and flow-controlled circulation bath from time 0 to 180 min.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cold exposure
Description: The liquid-conditioned tube suit will be perfused with 18°C water using a temperature- and flow-controlled circulation bath from time 0 to 180 min.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cold exposure
Description: The liquid-conditioned tube suit will be perfused with 18°C water using a temperature- and flow-controlled circulation bath from time 0 to 180 min.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cold exposure
Description: The liquid-conditioned tube suit will be perfused with 18°C water using a temperature- and flow-controlled circulation bath from time 0 to 180 min.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral Nicotinic acid
Description: A total of 500 mg of nicotinic acid will be given orally, at a rate of 2 doses of 150 mg and 2 doses of 100 mg: one dose of 150 mg at time 0 and 60 minutes, one dose of 100 mg at time 120 minutes and 180 minutes.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral Nicotinic acid
Description: A total of 500 mg of nicotinic acid will be given orally, at a rate of 2 doses of 150 mg and 2 doses of 100 mg: one dose of 150 mg at time 0 and 60 minutes, one dose of 100 mg at time 120 minutes and 180 minutes.
Study: NCT06075589

Intervention type: BEHAVIORAL
Intervention: Education for Intervention
Description: Participants watch two fifteen-minute educational videos and receive a mental health resource information sheet on study.

Intervention type: BEHAVIORAL
Intervention: Best Practice
Description: Patients receive enhanced treatment as usual and receive a mental health resource information sheet on study.
Study: NCT06099561

Intervention type: BEHAVIORAL
Intervention: National specialized medical care unit for severe self-harm behaviour-Consultation model
Description: Extensive assessments. Consultation and training for existing treatment providers and caregivers. Network-meetings for providers and caregivers.
Study: NCT04472299

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine 0.2% Injectable Solution
Description: Patients in the intervention group will have ultrasound guided bilateral T3 paravertebral catheters placed prior to surgery. Prior to surgery, these patients will have 5ml of 1.5% lidocaine with 1:200,000 epinephrine injected in each catheter. Ropivacaine 0.2% will be administered via programmed intermittent bolus of 7ml every 60 minutes through each catheter during and after surgery.
Study: NCT06467461

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Skin biopsy
Description: Skin biopsy to detect systemic alpha-synuclein pathology in 5-HT RBD

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Speech testing
Description: Speech Testing to quantify evolving signs of 5-HT RBD

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Ultra high field 7T MRI
Description: 7T MRI to examine 5-HT RBD for evidence of brainstem neurodegeneration
Study: NCT06298136

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: mindfulness-based intervention
Description: Audio exercises as homework assignment will be included. Four instructor-led online real time sessions are provided

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: child behavior management
Description: worksheet will be provided to guide parents and children in behavior change. Four instructor-led online real time sessions are provided.
Study: NCT06418490

Intervention type: DEVICE
Intervention: Three-dimensional visualization technology
Description: Three-dimensional reconstruction technology is a software that can collect CT and MRI data, perform image segmentation and three-dimensional reconstruction of the liver, gallbladder, dilated bile ducts, pancreas, venous, and arterial systems step by step. The software is called Abdominal Medical Image 3D Visualization Software (MI-3DVS, software copyright registration number: 2008SR18798).The AR-ANS (Software Copyright No.: 2018SR840555) is an intraoperative navigation system that integrates three-dimensional visualization technology.This modification provides visual guidance for surgeons when ligating or protecting critical vascular tissues during surgery.
Study: NCT05761990

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: POST ISOMTERIC RELAXATION TECHNIQUE
Description: POST ISOMETRIC RELAXATION TECHNIQUES~* Stretching the hypertonic muscle to the point when movement resistance is initially felt or just past the point of discomfort.~* For 5 to 10 seconds, a submaximal (10-20%) hypertonic muscle contraction is carried out away from the barrier while resistance is supplied in the other side. To help with this, the individual should breathe in.~* The individual is told to relax while breathing after the isometric contraction. After then, until the next barrier is reached, a gentle stretch is employed to pick up the slack.~* Starting with this new barrier, the procedure is carried out two or three more times.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: NOVEL STRETCHING
Description: NOVEL STRETCHING The NS will be performed in a supine posture for Group B participants. Participants will be instructed to open their knees while wearing a resistance band around their knees. Participant will be instructed to bridge as high as he can while keeping his shoulders 90 ° abducted and his elbows 90 ° flexed. By lifting the body weight upward, the bridging motion pins the scapula's medial border against the thorax without immediately squeezing or constricting the posterior shoulder bones. This position is thought to provide more flexibility of mobility while causing less discomfort. The subjects were instructed to hold this position while tightening or squeezing their gluteal muscles. They were also instructed to stretch by jerkily turning their shoulders inward as far as possible. Using the second hand, the stretch was pushed forward to the point of mild discomfort while contraction was maintained.
Study: NCT05771740

Intervention type: DEVICE
Intervention: Stemoscope (bluetooth sound amplifier)
Description: The bluetooth device will be placed in six locations on the front and six locations on the back of the chest and sound recordings stored for each location.

Intervention type: DEVICE
Intervention: Stemoscope (bluetooth sound amplifier)
Description: The bluetooth device will be placed in six locations on the front and six locations on the back of the chest and sound recordings stored for each location.
Study: NCT06395038

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Abatacept plus Aldesleukin
Description: CTLA4IgG plus Low dose Interleukin-2 (Aldesleukin) administration to modify immune responses

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Abatacept plus Aldesleukin
Description: CTLA4IgG plus Low dose Interleukin-2 (Aldesleukin) administration to modify immune responses